Search company, investor...


Founded Year




Date of IPO


About Gloryview

Gloryview (301396.SZ) provides building intelligence and information services including building intelligence, information system integration, and various related technical services for building owners and general construction contractors in various industries. The main products are building intelligent comprehensive services, technical services, and so on. The company was founded in 1997 and is based in Guangzhou, China.

Headquarters Location

7-8th Floor, Building B2 Creative Building, No. 162 Science Avenue

Guangzhou, Guangdong,



Missing: Gloryview's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Gloryview's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Gloryview Frequently Asked Questions (FAQ)

  • When was Gloryview founded?

    Gloryview was founded in 1997.

  • Where is Gloryview's headquarters?

    Gloryview's headquarters is located at 7-8th Floor, Building B2, Guangzhou.

  • What is Gloryview's latest funding round?

    Gloryview's latest funding round is IPO.

  • Who are the investors of Gloryview?

    Investors of Gloryview include Yimi, T-Rex Capital, Guangdong Technology Financial Group, Sino Pacific Capital, Qipu Investment and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.